- Home
- ONTF vs ARTV Comparison
ONTF vs ARTV Comparison
Compare ONTF & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONTF
- ARTV
- Stock Information
- Founded
- ONTF 1998
- ARTV 2019
- Country
- ONTF United States
- ARTV United States
- Employees
- ONTF N/A
- ARTV N/A
- Industry
- ONTF Computer Software: Prepackaged Software
- ARTV
- Sector
- ONTF Technology
- ARTV
- Exchange
- ONTF Nasdaq
- ARTV NYSE
- Market Cap
- ONTF 273.3M
- ARTV 274.4M
- IPO Year
- ONTF 2021
- ARTV 2024
- Fundamental
- Price
- ONTF $6.44
- ARTV $11.20
- Analyst Decision
- ONTF Hold
- ARTV Strong Buy
- Analyst Count
- ONTF 3
- ARTV 5
- Target Price
- ONTF $8.00
- ARTV $21.25
- AVG Volume (30 Days)
- ONTF 108.9K
- ARTV 52.5K
- Earning Date
- ONTF 11-07-2024
- ARTV 11-12-2024
- Dividend Yield
- ONTF N/A
- ARTV N/A
- EPS Growth
- ONTF N/A
- ARTV N/A
- EPS
- ONTF N/A
- ARTV N/A
- Revenue
- ONTF $150,738,000.00
- ARTV $2,601,000.00
- Revenue This Year
- ONTF N/A
- ARTV N/A
- Revenue Next Year
- ONTF N/A
- ARTV N/A
- P/E Ratio
- ONTF N/A
- ARTV N/A
- Revenue Growth
- ONTF N/A
- ARTV N/A
- 52 Week Low
- ONTF $5.37
- ARTV $9.68
- 52 Week High
- ONTF $8.35
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- ONTF 53.34
- ARTV N/A
- Support Level
- ONTF $6.16
- ARTV N/A
- Resistance Level
- ONTF $6.75
- ARTV N/A
- Average True Range (ATR)
- ONTF 0.24
- ARTV 0.00
- MACD
- ONTF -0.01
- ARTV 0.00
- Stochastic Oscillator
- ONTF 62.87
- ARTV 0.00
About ONTF ON24 Inc.
ON24 Inc provides a cloud-based digital experience platform that enables businesses to convert customer engagement into revenue through interactive webinar experiences, virtual event experiences, and multimedia content experiences. The company derives revenue from subscription agreements with customers for accessing the platform and related services. Geographically, it derives a majority of revenue from the United States.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.